查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571652

思覺失調症藥物市場規模、佔有率、趨勢分析報告：按類別、治療、分銷管道、地區和細分市場預測，2024-2030 年

Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), By Treatment, By Distribution Channels, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

思覺失調症藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球思覺失調症藥物市場規模預計將達到112億美元，2024年至2030年複合年成長率為5.3%。

總體而言，思覺失調症市場預計將受到藥物傳遞技術的改進、長效注射劑（LAI）的可用性以及尋求治療的患者數量增加的推動。支持新藥廣泛使用的主要特徵可能是起效快、患者容易取得、效率高、患者依從性高。

思覺失調症對患者、患者家庭和整個社會帶來沉重負擔。患者和醫生對精神疾病，特別是思覺失調症的認知的提高可能會增加新藥的市場滲透率。目前，第二代和第三代抗精神病藥物佔據了很大的市場佔有率。臨床試驗中的管道藥物旨在透過阻斷血清素和多巴胺受體的特定亞型來減輕症狀，調節升高的多巴胺水平，甚至改善記憶力。

思覺失調症市場的成長主要是由旨在治療思覺失調症症狀的後期研發線產品的出現所推動的，例如 Intra-Cellular Therapies 的 ITI-007 和 Alkermes 的 ALKS-3831。然而，思覺失調症治療領域存在大量未滿足的需求。由於缺乏對確切疾病機制的了解，突破性治療方法的發現受到阻礙。因此，需要創新藥物傳遞技術來治療這種使人衰弱的疾病。

思覺失調症藥物市場報告亮點

  • 到2023年，第二代抗精神病藥物將佔據最大的市場銷售佔有率，達到73.0%。思覺失調症藥物市場對第二代抗精神病藥物的需求正在增加，因為與第一代抗精神病藥物相比，第二代抗精神病藥物的安全性和有效性得到了改善。
  • 2023年，注射型抗精神病藥物治療領域佔最大的市場銷售佔有率。對注射型抗精神病藥物的需求正在上升，因為它們可以解決與這種疾病相關的一些挑戰。注射劑，尤其是長效注射劑 (LAI)，可穩定釋放藥物，有助於維持治療藥物水平並降低因錯過劑量而導致復發的風險（這在口服藥物中很常見）。
  • 2023年，醫院藥局領域佔據最大的市場銷售佔有率。醫院藥房能夠提供全面的護理，包括管理複雜的藥物治療方案和監測副作用。
  • 北美思覺失調症藥物市場佔最大市場銷售佔有率，2023年為39.0%。這是由於人們對思覺失調症和相關精神疾病的認知和診斷率提高。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章思覺失調症藥物市場變項、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 思覺失調症藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章思覺失調症藥物市場：類別估計與趨勢分析

  • 細分儀表板
  • 思覺失調症藥物市場：類別變異分析，2023 年和 2030 年

第5章思覺失調症藥物市場：治療估計與趨勢分析

  • 細分儀表板
  • 思覺失調症藥物市場：2023 年和 2030 年治療變異分析

第6章思覺失調症通路估算與趨勢分析

  • 細分儀表板
  • 思覺失調症管道變化分析

第7章思覺失調症藥物市場：區域估計與趨勢分析

  • 2023 年及 2030 年思覺失調症藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Johnson &Johnson
    • Bristol-Myers Squibb/Otsuka Pharma
    • AstraZeneca
    • Sumitomo Dainippon
    • Eli Lilly &Company
    • Alkermes
    • Vanda Pharma
    • Allergan
    • Pfizer
    • H. Lundbeck A/S
簡介目錄
Product Code: GVR-2-68038-222-8

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.3% from 2024 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.0% in 2023. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2023. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2023. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 39.0% in 2023. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Schizophrenia Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Schizophrenia Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Schizophrenia Drugs Market: Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
    • 4.2.1. Second-Generation Antipsychotics
      • 4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2. Risperdal (Risperidone)
        • 4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3. Invega (Paliperidone)
        • 4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.4. Zyprexa (Olanzapine)
        • 4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.5. Geodon (Ziprasidone)
        • 4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.6. Seroquel (Quetiapine)
        • 4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.7. Latuda (Lurasidone)
        • 4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.8. Aristada (Aripiprazole Lauroxil)
        • 4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.9. Fanapt (Iloperidone)
        • 4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.10. Saphris (Asenapine)
        • 4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.11. Vraylar (Cariprazine)
        • 4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Third-Generation Antipsychotics
      • 4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.2. Abilify (Aripiprazole)
        • 4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Others
    • 4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. First-Generation Antipsychotics
      • 4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Generics
      • 4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Schizophrenia Drugs Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
    • 5.2.1. Oral Antipsychotics
      • 5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Injectable Antipsychotics
      • 5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
    • 6.2.1. Hospital Pharmacies
      • 6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Retail Pharmacies
      • 6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Online Pharmacies
      • 6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Others
      • 6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Johnson & Johnson
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Sumitomo Dainippon
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Alkermes
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Vanda Pharma
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Allergan
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. H. Lundbeck A/S
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives